You are here
Avi Biopharma, Inc.
UEI: N/A
# of Employees: N/A
HUBZone Owned: No
Socially and Economically Disadvantaged: No
Woman Owned: No
Award Charts
Award Listing
-
Apoptotic Regulation of Lymphocyte Responses
Amount: $107,000.00DESCRIPTION (provided by applicant): The response of lymphocytes to antigen stimulation is characterized by proliferation of an antigen-sensitive lymphocyte population, subsequent differentiation to s ...
SBIRPhase I2005Department of Health and Human Services National Institutes of Health -
Antisense Antiviral Agent for West Nile Infections
Amount: $364,696.00DESCRIPTION (provided by applicant): AVI BioPharma has been developing an antisense phosphorodiamidate morpholino oligomer, AVI-4020 for the treatment of West Nile Virus. AVI-4020 has been shown both ...
SBIRPhase I2005Department of Health and Human Services National Institutes of Health -
Morpholino Antisense Drugs for Hepatitis C Virus
Amount: $164,078.00DESCRIPTION (provided by applicant): Hepatitis C Virus (HCV) causes a persistent infection in most humans exposed to the virus. HCV infection in time can lead to cirrhosis and hepatocellular carcinom ...
STTRPhase I2004Department of Health and Human Services National Institutes of Health -
Morpholino Antisense Drugs for Hepatitis C Virus
Amount: $164,078.00DESCRIPTION (provided by applicant): Hepatitis C Virus (HCV) causes a persistent infection in most humans exposed to the virus. HCV infection in time can lead to cirrhosis and hepatocellular carcinom ...
SBIRPhase I2004Department of Health and Human Services National Institutes of Health -
Inhibition of Androgen Receptor to treat Prostate Cancer
Amount: $250,000.00DESCRIPTION (provided by applicant): Prostate cancer is the second leading cause of cancer death in US men. Prostate cancer is highly dependent on androgen stimulation mediated through the androgen ...
SBIRPhase I2003Department of Health and Human Services National Institutes of Health -
Antisense Morpholino Oligomers to Treat Retinopathy
Amount: $100,000.00DESCRIPTION (provided by applicant): The broad, long-term objectives of the application are to develop antisense inhibitors of retinopathy and document their mechanism(s) of action. Retinopathy is a s ...
SBIRPhase I2003Department of Health and Human Services National Institutes of Health -
N/A
Amount: $0.00N/A
STTRPhase I2000Department of Health and Human Services National Institutes of Health -
N/A
Amount: $424,266.00N/A
STTRPhase II2000Department of Health and Human Services National Institutes of Health -
N/A
Amount: $98,415.00N/A
SBIRPhase I2000Department of Health and Human Services National Institutes of Health -
THERAPEUTIC APPLICATIONS OF PERFLUOROCARBON MICROBUBBLES
Amount: $98,771.00N/A
STTRPhase I1998Department of Health and Human Services